ImmunoPrecise Antibodies Ltd. (IPA)

Market Cap	11.13M
Revenue (ttm)	17.44M
Net Income (ttm)	-20.10M
Shares Out	28.83M
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	165,320
Open	0.408
Previous Close	0.408
Day's Range	0.366 - 0.408
52-Week Range	0.350 - 2.600
Beta	0.27
Analysts	Strong Buy
Price Target	6.00 (+1,454.81%)
Earnings Date	Dec 12, 2024

About IPA

ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company als...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 3, 2017
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: IPA
• Website: https://www.ipatherapeutics.com

Financial Performance

In 2024, ImmunoPrecise Antibodies's revenue was 24.52 million, an increase of 18.65% compared to the previous year's 20.67 million. Losses were -27.18 million, 2.32% more than in 2023.

Financial numbers in CAD

Analyst Forecast

According to 2 analysts, the average rating for IPA stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 1,454.81% from the latest price.

Price Target

$6.0

(1,454.81% upside)

Analyst Consensus: Strong Buy